SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today that QSYMIA® (phentermine and topiramate extended-release capsules ...

That’s why doctors are encouraging adults and adolescents with obesity to consider taking prescription medicine in combination with making lifestyle changes, including a reduced-calorie diet and more ...

The pill, called Qsymia, is designed for those who are overweight and have at least one weight-related condition, such as high blood pressure or diabetes. It is expected to help them lose 10 percent ...

Add Yahoo as a preferred source to see more of our stories on Google. Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past few ...

"When you add the two together you get very, very good weight loss," said Dr. Louis Aronne, New York Presbyterian Hospital. It worked for 57-year-old Gwendolyn Barton, who'd tried just about ...

If you have obesity and are curious whether a weight loss medication could help you improve your health, there are a number of weight loss pills on the market to consider, both old and new.

- Postmarketing requirement fulfilled based on data demonstrating QYSMIA® reduces blood pressure - CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and Drug ...

(NewsNation) — As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug Administration. Most prescription weight-loss drugs work by ...

Starting today, the newly FDA-approved diet drug Qsymia is available by prescription. Made by Vivus Inc., the weight-loss pill is approved for obese patients with a body mass index (BMI) of 30 or ...

CAMPBELL, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing ...

CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and Drug Administration has removed the requirement for a cardiovascular outcome trial for its ...